ストックスクリーナーアプリを入手
0.00
100.00%
-90.00
前日終値:
$90.00
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$6.83B
収益：
$35.93M
当期純損益:
$-244.56M
株価収益率:
0.00
EPS:
-3.95
ネットキャッシュフロー:
$-157.31M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$97.14
Merus N V Stock (MRUS) Company Profile
Compare MRUS vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
0.00 | 6.83B | 35.93M | -244.56M | -157.31M | -3.95 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-08-25 | 開始されました | Alliance Global Partners | Buy |
| 2025-02-13 | 開始されました | Piper Sandler | Overweight |
| 2025-02-07 | 開始されました | Wells Fargo | Overweight |
| 2024-11-21 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-03-28 | 開始されました | Truist | Buy |
| 2024-03-04 | 繰り返されました | Needham | Buy |
| 2023-11-02 | 開始されました | Canaccord Genuity | Buy |
| 2023-08-21 | 開始されました | TD Cowen | Outperform |
| 2022-08-02 | 開始されました | Stifel | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Needham | Buy |
| 2021-11-17 | 再開されました | Guggenheim | Buy |
| 2021-06-07 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-08 | 開始されました | William Blair | Outperform |
| 2021-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-06-26 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 再開されました | Guggenheim | Buy |
| 2019-06-28 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 再開されました | Guggenheim | Buy |
| 2019-04-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-03-21 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-12-22 | アップグレード | Citigroup | Neutral → Buy |
| 2016-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-06-13 | 開始されました | Citigroup | Buy |
| 2016-06-13 | 開始されました | Guggenheim | Buy |
| 2016-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Merus N V (MRUS) 最新ニュース
Trade Report: Is Merus NV on track to beat earnings2026 Short Interest & Daily Momentum Trading Reports - baoquankhu1.vn
Aug Weekly: Is Merus NV being accumulated by smart money2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Merus NVInflation Watch & Reliable Intraday Trade Alerts - baoquankhu1.vn
Merus NV Stock: Genmab Acquisition Deal at $97 Per Share Reshapes Biotech Investment Landscape for N - AD HOC NEWS
Bank Watch: Is Merus NV on track to beat earningsWeekly Investment Report & Capital Efficiency Focused Strategies - baoquankhu1.vn
Bull Run: Can Merus NV reach all time highs this year2026 Buyback Activity & Safe Entry Zone Tips - baoquankhu1.vn
Wells Fargo Downgrades Merus N.V. (MRUS) - MSN
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Stock Recap: Can Merus NV reach all time highs this yearRate Hike & Target Return Focused Stock Picks - baoquankhu1.vn
Merus NV Stock (ISIN: NL0011375928) Gains Momentum on Bispecific Antibody Pipeline Progress - AD HOC NEWS
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race - MSN
Growth Review: Is Merus NV a good ESG investment2026 Setups & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Precision Trading with Merus N.v. (MRUS) Risk Zones - Stock Traders Daily
How Merus N.V. stock reacts to bond yieldsTrade Analysis Report & Low Risk Profit Maximizing Plans - Naître et grandir
Dividend Watch: Is Merus NV being accumulated by smart moneyMarket Sentiment Review & Consistent Profit Trade Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Aug Summary: Is Merus NV a good ESG investment2025 Big Picture & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Biotechnology Gem With 7.78% Potential Upside - DirectorsTalk Interviews
Genmab Publishes 2025 Annual Report - GlobeNewswire
Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) - MSN
What is Merus N.V. s 5 year growth outlookWeekly Stock Summary & AI Enhanced Trading Signals - mfd.ru
Targets Report: Will Merus N.V. stock outperform tech sector in 2025Weekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Genmab Prepares For Two Product Launches In 2027, Both From Recent Deals - Citeline News & Insights
Is Merus N.V. stock trading near support levelsJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Published on: 2026-02-10 12:58:35 - mfd.ru
Can Merus N.V. reach all time highs this year2025 Major Catalysts & Proven Capital Preservation Methods - mfd.ru
Merus N.V. (MRUS) Stock Analysis: Weighing The 7.78% Potential Upside For Investors - DirectorsTalk Interviews
Merus N.V. (MRUS) Stock Analysis: Exploring the Potential 7.78% Upside in the Biotech Sector - DirectorsTalk Interviews
Analyst Downgrade: Is Merus NV gaining market shareJuly 2025 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn
Growth Recap: What are Can Fite BioPharma Ltd Depositary Receipts technical support levels - baoquankhu1.vn
Aug Ideas: Is Merus NV a turnaround storyJuly 2025 PreEarnings & AI Enhanced Execution Alerts - baoquankhu1.vn
Fourteen option delistings on January 21st - TipRanks
Merus N.V. (MRUS) Stock Analysis: Biotechnology Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Piper Sandler sets $84 target on Merus stock, cites drug potential - MSN
S P Trends: How does Merus NV correlate with Nasdaq2025 Technical Overview & Target Return Focused Picks - baoquankhu1.vn
Merus N.V. (MRUS) Stock Analysis: Healthcare Innovator With 7.78% Upside Potential - DirectorsTalk Interviews
Gap Down: Is Merus N.V. stock a safe haven assetJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Bộ Nội Vụ
Aug Breakouts: Why Merus NV stock could benefit from AI revolutionJuly 2025 Final Week & Stock Market Timing Techniques - Bộ Nội Vụ
Risk Report: Will Merus NV stock benefit from M A activityQuarterly Market Summary & Pattern Based Trade Signal System - Bộ Nội Vụ
Aug Shorts: Is Merus NV stock a buy on dipsEarnings Growth Summary & Low Risk Entry Point Tips - Bộ Nội Vụ
(MRUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Published on: 2026-01-13 00:53:02 - Улправда
Merus N.V.Common Shares (NQ: MRUS - FinancialContent
How Merus N.V. stock trades before earnings2025 Market Overview & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Net current asset value per share of Merus N.V. – MUN:2GH - TradingView — Track All Markets
Why Merus N.V. stock attracts high net worth investorsQuarterly Performance Summary & Reliable Entry Point Trade Alerts - ulpravda.ru
Is Merus N.V. (2GH) stock positioned for digital growth eraDay Trading Setups & Free Tools to Monitor Market Corrections - Улправда
Merus N.V. Financial Disclosures & Filings - TradingView — Track All Markets
Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations - DirectorsTalk Interviews
Genmab Announces $2.5 Billion Note Offering for Merus Acquisition - MSN
What analysts say about Merus NV stockTrading Volume Surges & Outstanding Investment Returns - earlytimes.in
Merus N V (MRUS) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):